benzyl benzyl-H-phosphinate | 880335-39-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl benzyl-H-phosphinate
• 英文别名: benzyl benzylphosphinate；[Benzyl(oxido)phosphaniumyl]oxymethylbenzene
• CAS: 880335-39-7
• 化学式: C₁₄H₁₅O₂P
• 分子量: 246.246
• InChiKey: SBRYYIBYHYKRGX-UHFFFAOYSA-N

物化性质

• 沸点：
  383.4±45.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyl benzyl-H-phosphinate 在 5percent Pd/C 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 22.0h， 生成 2-[[(phenylmethyl)hydroxyphosphinyl]methyl]pentanedioic acid
  参考文献：
  名称：

  Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors

  摘要：

  A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive mc del of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.

  DOI：

  10.1021/jm0001774
• 作为产物：
  描述：

  溴甲苯 、 alkaline earth salt of/the/ methylsulfuric acid 在 ammonium phosphite 、 N,N'-二环己基碳二亚胺 、 六甲基二硅氮烷 作用下， 以 二氯甲烷 为溶剂， 反应 33.0h， 生成 benzyl benzyl-H-phosphinate
  参考文献：
  名称：

  Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors

  摘要：

  A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive mc del of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.

  DOI：

  10.1021/jm0001774

文献信息

• INHIBITORS OF INFLUENZA VIRUSES REPLICATION
  申请人：Charifson Paul S.

  公开号：US20120171245A1

  公开（公告）日：2012-07-05

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒的复制、减少生物样本或患者中流感病毒量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的由结构公式（I）表示的化合物： 或其药用可接受盐，其中结构公式（IA）的值如本文所述。由结构公式（IA）或其药用可接受盐表示的化合物，其中结构公式（IA）的值如本文所述。药物组合物包括有效量的上述化合物或其药用可接受盐，以及药用可接受载体、佐剂或车辆。
• Chiral Guanidinium Salt Catalyzed Enantioselective Phospha-Mannich Reactions
  作者：Xiao Fu、Wei-Tian Loh、Yan Zhang、Tao Chen、Ting Ma、Hongjun Liu、Jianmin Wang、Choon-Hong Tan

  DOI：10.1002/anie.200903971

  日期：2009.9.21

  Zero, one, or two? Guanidinium catalyst 1⋅HBArF4 (ArF=3,5‐(CF3)2C6H3, Bn=benzyl, Ts=4‐toluenesulfonyl) was obtained in a single step from a commercially available diamine. By using this catalyst an asymmetric phospha‐Mannich reaction has been developed, involving secondary phosphine oxides and H‐phosphinates as the P nucleophile. A series of enantiomerically enriched α‐amino phosphine oxides (2), α‐amino

  零，一或两个？胍催化剂1⋅ HBAR ˚F 4（AR ˚F = 3,5-（CF 3）2 C ^ 6 ħ 3在从可商购的二胺单个步骤获得，BN =苄基，TS = 4甲苯磺酰基）。通过使用这种催化剂，已经开发了不对称的膦-曼尼希反应，涉及仲膦氧化物和H-次膦酸酯作为P亲核试剂。制备了一系列对映异构体富集的α-氨基膦氧化物（2），α-氨基次膦酸酯和H-次膦酸酯，它们含有一个P-手性中心。
• Direct Monoalkylation of Alkyl Phosphinates to Access H-Phosphinic Acid Esters
  作者：Jean-Luc Montchamp、Isabelle Abrunhosa-Thomas、Patrice Ribière、Alicia C. Adcock

  DOI：10.1055/s-2005-924768

  日期：——

  Simple alkyl phosphinates prepared by the silicate esterification method can be alkylated under Barbier-like conditions with butyl lithium at -78 °C followed by warming to room temperature. The method is limited to the more reactive electrophile such as allylic bromides and alkyl iodides. With these electrophiles good yields of H-phosphinic acid esters are generally obtained in a straightforward manner

  通过硅酸酯化方法制备的简单烷基次膦酸盐可以在类似巴比尔的条件下与丁基锂在 -78 °C 下烷基化，然后升温至室温。该方法仅限于反应性更强的亲电子试剂，例如烯丙基溴化物和烷基碘化物。使用这些亲电子试剂，通常以简单的方式获得高产率的 H-次膦酸酯。
• Inhibitors of influenza viruses replication
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10039762B2

  公开（公告）日：2018-08-07

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的结构式（I）所代表的化合物： 或其药学上可接受的盐，其中结构式（IA）的值如本文所述。一种化合物由结构式（IA）或其药学上可接受的盐表示，其中结构式（IA）的值如本文所述。药物组合物包含有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• OIL-SOLUBLE PLANT MICRONUTRIENTS
  申请人：Huntsman Petrochemical LLC

  公开号：EP3500544A1

  公开（公告）日：2019-06-26